2023-06-01 08:32:17 ET
-
VolitionRx ( NYSE: VNRX ) prices an underwritten public offering of shares, whereby underwriters will be granted a 30-day option to purchase up to an additional 15% shares.
-
The final terms and size of the offering will depend on market and other conditions.
-
Net proceeds will be deployed for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions.
For further details see:
VolitionRx proposes public offering